Roivant Sciences Ltd (NASDAQ: ROIV) has a higher price-to-earnings ratio of 2.03x compared to its average ratio, The 36-month beta value for ROIV is at 1.30. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ROIV is 551.47M, and currently, shorts hold a 5.61% of that float. The average trading volume for ROIV on April 23, 2024 was 7.38M shares.
ROIV) stock’s latest price update
Roivant Sciences Ltd (NASDAQ: ROIV) has seen a rise in its stock price by 1.34 in relation to its previous close of 10.46. However, the company has experienced a -2.21% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-01-07 that Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievements include the sale of Telavant to Roche, the successful performance of Vtama cream for psoriasis, and advancements in clinical trials for atopic dermatitis and IMVT-1402 antibody development. Despite the lack of immediate catalysts and ongoing cash burn, the stock trades at a substantial discount relative to its sector, making it a “buy” at current levels.
ROIV’s Market Performance
Roivant Sciences Ltd (ROIV) has experienced a -2.21% fall in stock performance for the past week, with a 3.31% rise in the past month, and a 2.42% rise in the past quarter. The volatility ratio for the week is 2.89%, and the volatility levels for the past 30 days are at 3.63% for ROIV. The simple moving average for the past 20 days is -2.23% for ROIV’s stock, with a -0.42% simple moving average for the past 200 days.
Analysts’ Opinion of ROIV
Many brokerage firms have already submitted their reports for ROIV stocks, with Wolfe Research repeating the rating for ROIV by listing it as a “Outperform.” The predicted price for ROIV in the upcoming period, according to Wolfe Research is $17 based on the research report published on February 15, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ROIV reach a price target of $20. The rating they have provided for ROIV stocks is “Overweight” according to the report published on January 05th, 2024.
Deutsche Bank gave a rating of “Buy” to ROIV, setting the target price at $14 in the report published on December 12th of the previous year.
ROIV Trading at -3.10% from the 50-Day Moving Average
After a stumble in the market that brought ROIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.94% of loss for the given period.
Volatility was left at 3.63%, however, over the last 30 days, the volatility rate increased by 2.89%, as shares surge +4.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.28% upper at present.
During the last 5 trading sessions, ROIV fell by -2.21%, which changed the moving average for the period of 200-days by -0.47% in comparison to the 20-day moving average, which settled at $10.86. In addition, Roivant Sciences Ltd saw -5.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ROIV starting from Venker Eric, who sale 96,950 shares at the price of $10.92 back on Feb 09 ’24. After this action, Venker Eric now owns 532,207 shares of Roivant Sciences Ltd, valued at $1,058,694 using the latest closing price.
Ramaswamy Vivek, the 10% Owner of Roivant Sciences Ltd, sale 3,000,000 shares at $11.05 during a trade that took place back on Jan 02 ’24, which means that Ramaswamy Vivek is holding 51,929,426 shares at $33,150,000 based on the most recent closing price.
Stock Fundamentals for ROIV
Current profitability levels for the company are sitting at:
- 39.17 for the present operating margin
- 0.88 for the gross margin
The net margin for Roivant Sciences Ltd stands at 35.09. The total capital return value is set at 0.68. Equity return is now at value 123.54, with 91.47 for asset returns.
Based on Roivant Sciences Ltd (ROIV), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -1.65. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 133.42.
Currently, EBITDA for the company is -1.11 billion with net debt to EBITDA at 6.23. When we switch over and look at the enterprise to sales, we see a ratio of 19.29. The receivables turnover for the company is 1.95for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 27.79.
Conclusion
In conclusion, Roivant Sciences Ltd (ROIV) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
